Immuno-oncology targets

TARGET DISEASE INDICATIONS STATUS – KEY DATA MILESTONE
ZM008

Lead Molecule
New target. Functions through NK cell based therapy

Prostate Cancer,
B cell lymphoma, glioma, rheumatoid arthritis
  • Strong in vivo efficacy
  • Ongoing clinical risk mitigation studies
  • Development management team in place
IND filing in
Q2 2020
ZM012

mAb target. Functions through tumour associated antigen/NK cell receptor

Lymphoma and other Undisclosed indications Unique Clone identification in process Target identity in Q4 2019
ZM014

mAb target. Functions through tumour NK cell receptor

Lymphoma Unique Clone identification in process Target identity in
Q4 2019

2

Molecules for NK cell and cell targets under development

Future targets of interest

Other Innate Immunity Targets

Novel Targets

Academic collaboration in the US